Literature DB >> 2189761

Dependence of antigen expression on functional state of beta-cells.

K Aaen1, J Rygaard, K Josefsen, H Petersen, C H Brogren, T Horn, K Buschard.   

Abstract

Antigen expression corresponding to anti-islet cell surface monoclonal antibodies IC2 and A2B5 was studied. IC2 is a rat-rat hybridoma autoantibody produced from the BB rat; among islet cells, IC2 is beta-cell specific. A2B5 is an anti-ganglioside antibody described as labeling beta-cells. Islets of Langerhans from Lewis rats were isolated and cultured for 18 h in RPMI-1640 with five different glucose concentrations (2.2, 3.3, 5.5, 11.1, and 18.3 mM). In some experiments, islets were precultured for 2 or 3 days. After isolation of islet cells and antibody labeling, the percent of IC2+ beta-cells in the different groups increased from 33.3, 34.5, 40.9, and 57.2 to 58.6% (P less than 10(-6). For A2B5, the percent of labeled islet cells increased from 37.4, 41.8, 46.7, and 53.8 to 56.2% (P less than 10(-4). Thus, increasing glucose concentration leading to higher beta-cell activity implies an increase in antigen expression. Neither A2B5 nor IC2 reacts with insulin, as shown by absorption experiments and immune electron microscopy of binding sites. Electron microscopy of IC2-gold-labeled islet cells substantiated the beta-cell specificity of IC2. In conclusion, expression of the corresponding antigens to IC2 and A2B5 depends on the functional state of the beta-cells; because this has been shown to be an important factor in the development of insulin-dependent diabetes, our findings may be of potential pathogenetic interest.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189761     DOI: 10.2337/diab.39.6.697

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  24 in total

Review 1.  Toward closing the loop: an update on insulin pumps and continuous glucose monitoring systems.

Authors:  Tandy Aye; Jen Block; Bruce Buckingham
Journal:  Endocrinol Metab Clin North Am       Date:  2010-09       Impact factor: 4.741

Review 2.  Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis.

Authors:  Linda Yip; C Garrison Fathman
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

3.  In utero undernutrition reduces diabetes incidence in non-obese diabetic mice.

Authors:  A Oge; E Isganaitis; J Jimenez-Chillaron; C Reamer; R Faucette; K Barry; R Przybyla; M E Patti
Journal:  Diabetologia       Date:  2007-03-17       Impact factor: 10.122

Review 4.  Imaging beta-cell mass and function in situ and in vivo.

Authors:  Lu Yang; Wei Ji; Yanhong Xue; Liangyi Chen
Journal:  J Mol Med (Berl)       Date:  2013-05-23       Impact factor: 4.599

5.  Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice.

Authors:  D G Karounos; J S Bryson; D A Cohen
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

6.  Sugar intake is associated with progression from islet autoimmunity to type 1 diabetes: the Diabetes Autoimmunity Study in the Young.

Authors:  Molly M Lamb; Brittni Frederiksen; Jennifer A Seifert; Miranda Kroehl; Marian Rewers; Jill M Norris
Journal:  Diabetologia       Date:  2015-06-07       Impact factor: 10.122

7.  Glucose activation of islets of Langerhans up-regulates Toll-like receptor 5: possible mechanism of protection.

Authors:  C Weile; K Josefsen; K Buschard
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 8.  The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure.

Authors:  Bart O Roep
Journal:  Diabetologia       Date:  2003-03-22       Impact factor: 10.122

9.  Insulin resistance is a risk factor for progression to type 1 diabetes.

Authors:  S Fourlanos; P Narendran; G B Byrnes; P G Colman; L C Harrison
Journal:  Diabetologia       Date:  2004-10-06       Impact factor: 10.122

Review 10.  Beta-cell protection and therapy for latent autoimmune diabetes in adults.

Authors:  Simona Cernea; Raffaella Buzzetti; Paolo Pozzilli
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.